BioNxt Reports Expanded Research, Development and Commercialization Capability with Centralized Munich Laboratory
VANCOUVER, BC / ACCESS Newswire / May 13, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, is pleased to announce the integration of its research, development and commercialization activities to the Gen-Plus GmbH & Co. KG (Gen-Plus) Contract Research and Development Organization (CRDO) in Munich, Germany. The move provides BioNxt with enhanced R&D capabilities, collaboration opportunities, and accelerated innovation potential within a major European biotech hub.
The Company seeks to leverage the advanced and innovative infrastructure of the Gen-Plus Laboratory and harness the facility's 1,000 square meters of state-of-the-art space designed for high-potency active pharmaceutical ingredients and GMP-compliant processes. The lab's specialized equipment, including advanced technologies for solid and semi-solid dosage forms and capabilities in drug printing, will empower BioNxt to maximize the potential of its proprietary drug delivery systems, neurodegenerative disease therapeutics, and next-generation biomedical technologies.
In the coming weeks, BioNxt and Gen-Plus will be working together closely and focused on the development and commercialization of the Company's lead product, BNT23001, a sublingual thin-film formulation of Cladribine for the treatment of multiple sclerosis (MS). Preparation activities for the planned human bioequivalence study include placebo trials, product and technology transfer, upscaling of manufacturing, and analytical validation of the active pharmaceutical ingredient.
About Gen-Plus GmbH & Co. KG
Gen-Plus, headquartered in Munich, Germany, is a premier Contract Research and Development Organization (CRDO) with over 25 years of experience in pharmaceutical formulation and development. The company operates a 1,000-square-meter state-of-the-art laboratory equipped for handling high-potency active pharmaceutical ingredients and licensed for GMP-compliant production, including narcotics.
Gen-Plus specializes in developing solid and semi-solid dosage forms, transdermal patches, and oral thin films, offering end-to-end services from feasibility studies to clinical trial supply production. The company leverages advanced technologies such as hot-melt extrusion, drug printing, and amorphization of APIs to deliver comprehensive pharmaceutical solutions.
Committed to innovation, Gen-Plus collaborates with leading European research institutions and biotech companies to drive advancements in pharmaceutical solutions. The company's expertise and cutting-edge infrastructure make it a trusted partner in accelerating drug development and commercialization.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 778.598.2698
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains "forward-looking information" within the meaning of applicable securities laws. Forward-looking information is based on management's expectations, estimates, projections, and assumptions as of the date of this press release. It is subject to significant risks, uncertainties, and other factors that could cause actual results or events to differ materially from those expressed or implied. These risks and uncertainties include, but are not limited to, general economic conditions, market conditions, regulatory risks, technological advancements, and other factors described in the Company's public disclosure filings.
Readers are cautioned not to place undue reliance on forward-looking information, as actual outcomes may differ significantly from those expressed or implied, due to various factors beyond the Company's control. The Company undertakes no obligation to update or revise any forward-looking information, except as required by law.
SOURCE: BioNxt Solutions Inc.
View the original press release on ACCESS Newswire
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Loar Holdings Inc. Reports Q1 2025 Record Results and Upward Revision to 2025 Outlook13.5.2025 08:30:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / May 13, 2025 / Loar Holdings Inc. (NYSE:LOAR) (the "Company," "Loar," "we," "us" and "our"), reported record results for the first quarter of 2025. First Quarter 2025 Net sales of $114.7 million, up 24.8% compared to the prior year's quarter. Net income of $15.3 million, up $13.1 million compared to the prior year's quarter. Diluted earnings per share of $0.16. Adjusted EBITDA of $43.1 million, up 30.6% compared to the prior year's quarter. Net income margin for the quarter improved to 13.4% compared to the prior year's quarter net income margin of 2.4%. Adjusted EBITDA Margin for the quarter improved to 37.6% compared to 36.0% for the prior year's quarter. Adjusted Earnings Per Share of $0.20. "We began 2025 with excellent momentum from strong demand across our end-markets," stated Dirkson Charles, Loar CEO and Executive Co-Chairman of the Board of Directors. "In the quarter, sales to our Original Equipment, Commercial Aftermarket and Defense marke
OMP's Unison Planning Achieves SAP(R) Certified Integration with RISE with SAP S/4HANA(R) Cloud13.5.2025 07:00:00 CEST | Press release
ANTWERPEN, BE / ACCESS Newswire / May 13, 2025 / OMP, a global leader in supply chain planning solutions, announced today that its Unison PlanningTM platform has achieved SAP® certification as integrated with RISE with SAP S/4HANA® Cloud. Continuing its long history of providing SAP-certified integration, this milestone confirms Unison Planning's full support for S/4HANA environments and its compatibility with RISE with SAP. The integration delivers seamless, near-real-time connectivity between SAP and Unison Planning's advanced supply chain capabilities, reinforcing OMP's role as a trusted partner for navigating complex planning environments. "Achieving this certification highlights our commitment to innovation and enterprise-grade reliability," says Tom Wouters, Chief Product Officer at OMP. "It confirms our ability to support global businesses in their digital transformation journeys, especially those migrating to S/4HANA with RISE with SAP." OMP was recently recognized as a Leader
Market Logic Software and Alchemy-RX Announce Strategic Partnership to Accelerate Transformation of Insights to Growth13.5.2025 02:00:00 CEST | Press release
BERLIN, DE / ACCESS Newswire / May 13, 2025 / Market Logic Software, the market-leading SaaS provider of insight management solutions, announces a strategic partnership with Alchemy-Rx, a growth consultancy. Together, the two firms will help brands unlock the full value of insights - transforming research and data into topline growth. This partnership brings together complementary capabilities: Market Logic's AI-powered technology platform DeepSights™ - which centralizes and synthesizes research across knowledge sources - and Alchemy-Rx's proven methods to turning those insights into high-impact ideas. While Market Logic enables organizations to uncover trusted insights faster and more effectively, Alchemy-Rx helps brands act on those insights to fuel incremental revenue. "DeepSights is best-in-class-when it comes to insight management," said Richard Davies, Co-Founder of Alchemy-Rx. "This partnership combines our strengths. Making sense of multiple data sources to discover an insight
MicroVision Announces First Quarter 2025 Results12.5.2025 16:05:00 CEST | Press release
REDMOND, WA / ACCESS Newswire / May 12, 2025 / MicroVision, Inc. (NASDAQ:MVIS), a technology pioneer delivering advanced perception solutions in autonomy and mobility, today announced its first quarter 2025 results. Key Business Highlights Established defense industry advisory board to accelerate strategic expansion and pursuit of revenue opportunities in the defense tech and military sectors. Elevated momentum toward near-term revenue opportunities from multiple leading industrial companies in the autonomous mobile robot (AMR) and automated guided vehicle (AGV) sector. Deepened executive leadership expertise, onboarding Glen DeVos, former CTO of Aptiv, as MicroVision's Chief Technology Officer, leading the Company's innovative product roadmapping and enhanced go-to-market strategy. Continued engagement with top-tier global automotive OEMs, with seven high-volume RFQs for passenger vehicles and custom development opportunities. Ramped production to meet anticipated volume demand, ensur
Nestlé and OMP Showcase Approach to Future-Ready Supply Chain at Gartner Supply Chain Symposium/Xpo in Barcelona9.5.2025 04:20:00 CEST | Press release
BARCELONA, ES / ACCESS Newswire / May 9, 2025 / OMP, a leading provider of supply chain planning solutions, invites attendees of the Gartner Supply Chain Symposium/Xpo™ 2025 to attend Nestlé's solution provider session on May 19. The presentation will highlight how the company is transforming its supply chain across brands and regions using OMP's Unison PlanningTM. In this session, Shannon Novack, Supply Chain Excellence Expert at Nestlé, will share how the global food and beverage leader is reimagining its supply chain planning to meet increasing customer expectations in a fast-changing business environment. By leveraging advanced planning technology like Unison Planning, managing organizational change, and scalingfuture-fit capabilities, Nestlé is delivering real results. Attendees will gain valuable insights into how the company is driving adoption, overcoming transformation challenges, and aligning technology speed with organizational agility. The Gartner Supply Chain Symposium/Xpo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom